News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,461 Results
Type
Article (672)
Company Profile (1)
Press Release (12788)
Section
Business (3540)
Career Advice (2)
Deals (860)
Drug Development (1292)
Employer Resources (1)
FDA (259)
Job Trends (135)
News (5975)
Policy (545)
Tag
Academia (22)
Alliances (1645)
ALS (2)
Alzheimer's disease (11)
Antibody-drug conjugate (ADC) (4)
Approvals (268)
Artificial intelligence (4)
Autoimmune disease (4)
Best Places to Work (105)
Biosimilars (7)
Bladder cancer (2)
Breast cancer (11)
Cancer (60)
Cardiovascular disease (3)
Career advice (2)
CAR-T (2)
CDC (1)
Cell therapy (11)
Clinical research (1115)
Collaboration (42)
Compensation (11)
COVID-19 (101)
CRISPR (1)
C-suite (20)
Cystic fibrosis (1)
Data (84)
Depression (2)
Diabetes (3)
Diagnostics (140)
Drug discovery (3)
Drug shortages (1)
Earnings (916)
Employer resources (1)
Events (1176)
Executive appointments (10)
FDA (306)
Funding (20)
Gene editing (2)
Gene therapy (8)
GLP-1 (13)
Government (47)
Guidances (5)
Healthcare (323)
IgA nephropathy (1)
Immunology and inflammation (3)
Immuno-oncology (1)
Indications (2)
Infectious disease (103)
Influenza (1)
Intellectual property (5)
Interviews (1)
IPO (227)
Job creations (32)
Job search strategy (2)
Layoffs (4)
Legal (159)
Liver cancer (1)
Lung cancer (7)
Lymphoma (1)
Management (1)
Manufacturing (14)
Medical device (189)
Medtech (190)
Mergers & acquisitions (656)
Metabolic disorders (6)
mRNA (23)
Multiple sclerosis (5)
Neurodegenerative disease (1)
Neuropsychiatric disorders (1)
Neuroscience (24)
NextGen: Class of 2026 (46)
Non-profit (4)
Obesity (3)
Opinion (2)
Ovarian cancer (1)
Pain (8)
Pancreatic cancer (1)
Parkinson's disease (3)
Patents (5)
Patient recruitment (10)
People (856)
Pharmaceutical (1)
Phase 1 (369)
Phase 2 (493)
Phase 3 (406)
Pipeline (99)
Policy (1)
Postmarket research (41)
Preclinical (131)
Prostate cancer (3)
Psychedelics (1)
Radiopharmaceuticals (6)
Rare diseases (9)
Real estate (128)
Regulatory (416)
Reports (1)
Research institute (29)
Series A (6)
Service/supplier (1)
Startups (86)
Supply chain (1)
The Weekly (1)
Vaccines (27)
Date
Today (4)
Last 7 days (11)
Last 30 days (36)
Last 365 days (354)
2026 (103)
2025 (352)
2024 (456)
2023 (558)
2022 (1873)
2021 (1729)
2020 (1214)
2019 (758)
2018 (487)
2017 (662)
2016 (529)
2015 (749)
2014 (579)
2013 (492)
2012 (564)
2011 (503)
2010 (429)
Location
Africa (8)
Arizona (1)
Asia (620)
Australia (176)
California (65)
Canada (39)
China (3)
Delaware (9)
Europe (5533)
Florida (8)
Georgia (2)
Idaho (1)
Illinois (16)
Indiana (1)
Japan (20)
Kentucky (1)
Maryland (6)
Massachusetts (70)
Michigan (9)
New Jersey (30)
New York (10)
North Carolina (9)
Northern California (48)
Pennsylvania (87)
South America (17)
Southern California (9)
Texas (4)
United States (335)
Utah (8)
Washington State (1)
Wisconsin (1)
13,461 Results for "curevac gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CureVac Announces Voting Results of Extraordinary General Meeting
November 26, 2025
·
8 min read
Mergers & acquisitions
BioNTech Swallows Vaccine Rival CureVac in $1.25B All-Stock Acquisition
BioNTech will get CureVac’s early-stage cancer assets, including its mRNA-based glioblastoma therapy currently in Phase I development. CureVac had previously sued BioNTech for copyright infringement related to mRNA vaccine technology.
June 12, 2025
·
3 min read
·
Tristan Manalac
Press Releases
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
December 4, 2025
·
13 min read
Press Releases
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
November 24, 2025
·
18 min read
Press Releases
Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa
April 14, 2026
·
1 min read
Press Releases
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
December 18, 2025
·
7 min read
Press Releases
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
October 22, 2025
·
18 min read
Press Releases
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
November 27, 2025
·
15 min read
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Press Releases
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
August 18, 2025
·
11 min read
1 of 1,347
Next
